Shining light to kill cancer cells
Cancer remains one of the leading causes of death worldwide, however, advancements in science continue to bring hope through better treatment options.
One such option is photodynamic therapy (PDT), a promising and less invasive treatment that uses light, a special drug and oxygen molecules to target and destroy cancer cells.
PDT is a type of cancer treatment that combines a special drug called a 'photosensitiser' with light to destroy cancer cells.
The drug becomes active when exposed to a specific type of light, usually from a laser or LED (light-emitting diodes), and reacts with oxygen in the body. This reaction produces substances that kill cancer cells, disrupt nearby blood vessels and trigger a local immune response.
Unlike treatments such as chemotherapy or radiation, PDT is very precise, targeting only the cancer cells while sparing most healthy tissue.
It's especially useful for cancers close to the skin's surface or inside body cavities where light can reach.
PDT is also less painful than surgery, leaves minimal scarring and has fewer side effects.
Some photosensitisers have already been approved for treating certain pre-cancerous conditions and cancers in the United States and Europe. PDT works best for cancer cells that can be reached by light such as skin cancer, which means it's not suitable to treat all types of cancer.
Availability of PDT locally
In Malaysia, the use of PDT is gradually increasing as awareness of its benefits grows.
Since it is a minimally invasive healthcare technology, PDT is gaining attention as an alternative or complementary treatment to traditional therapies.
Although PDT isn't intended to replace surgery, chemotherapy or radiation, it's a valuable option for certain patients.
Experts believe that improvements in technology, such as better photosensitisers, will help expand the use of PDT.
However, more research is needed to fully establish its advantages over traditional treatments and its cost-effectiveness within Malaysia's healthcare system.
Healthcare providers and institutions are also working to make PDT more affordable and accessible, while educating patients about its benefits and limitations.
Is PDT effective?
PDT has been proven to work well for various cancers, including skin cancer, oesophageal cancer, lung cancer, bladder cancer, biliary tract cancer and head and neck cancers.
It's particularly helpful for managing symptoms in advanced or recurring cases that can't be cured.
For skin cancer, PDT offers an added benefit: it leaves the skin looking better after treatment compared to surgery or other options.
In some cases, PDT has also been found to improve survival rates and quality of life.
Side effects, such as light sensitivity, pain, redness, or itching, are usually mild and manageable.
Among PDT's uniqueness:
> Minimally-invasive: H elps avoid the need for major surgery, leading to faster recovery times and less discomfort.
> Precise targeting: The treatment focuses on cancer cells without harming most healthy tissues.
> F ewer side effects: Unlike chemotherapy, PDT doesn't cause nausea, hair loss, or other widespread side effects.
> Repeatable treatment: PDT can be safely repeated in the same area, unlike radiation therapy.
Challenges and future directions
While PDT has many advantages, it also has some limitations.
The treatment only works for cancers that can be reached by light, which means it's not suitable for all types of cancer.
Additionally, the photosensitising drugs used in PDT can make the skin and eyes sensitive to light for some time after treatment, requiring precautions like avoiding sunlight.
Looking ahead, researchers are working on developing more effective drugs and better ways to deliver light to tumours, which could make PDT even more effective.
Worldwide, efforts are being made to make PDT more affordable and available to patients.
In short, PDT is an innovative treatment for certain types of cancer.
It offers a less invasive and more targeted approach compared to traditional options. As awareness grows and technology improves, PDT has the potential to play a substantial role in cancer care.
While challenges remain, the future of PDT is bright, bringing hope to cancer patients everywhere.
Dr Lee Tze Yan is a senior lecturer and researcher in the field of biomedical science at the Institute of Medical Science Technology, Universiti Kuala Lumpur, Dr Nur Aininie Yusoh is a postdoctoral fellow in the Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, and Dr Loo Yan Shan holds a PhD in nanomedicine from Universiti Putra Malaysia, and is currently a research assistant in Monash University Malaysia. The information provided is for educational and communication purposes only, and should not be considered as medical advice. The Star does not give any warranty on accuracy, completeness, functionality, usefulness or other assurances as to the content appearing in this article. The Star disclaims all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
15 hours ago
- Malaysian Reserve
EPF weighs RM8b sale of UK private hospitals
Healthcare property has seen a flurry of interest this year as investors seek out alternative assets with long-term indexed-linked leases MALAYSIA'S Employees Provident Fund (EPF) is preparing to sell a portfolio of UK private hospitals that are valued at about £1.4 billion (RM8.03 billion). The fund has appointed broker Knight Frank to offer the 12 properties for sale, people with knowledge of the process said. The hospitals, which an EPF-led consortium bought for about £700 million in 2013, are operated by Spire Healthcare Group plc, the people said, asking not to be identified as the process is private. Representatives for EPF and Knight Frank declined to comment. Healthcare property has seen a flurry of interest this year as investors seek out alternative assets with long-term indexed-linked leases. KKR & Co is vying with Primary Health Properties plc to buy Assura plc, a UK landlord that mostly owns doctor surgeries as well as a portfolio of private hospitals that it bought for £500 million last year. Aedifica SA agreed on June 3 to buy rival Cofinimmo in a deal that creates a healthcare REIT with a combined gross asset value of more than €12 billion (RM58.04 billion). The use of private healthcare in the UK has grown as the country's National Health Service (NHS) struggles to bring down waiting lists that were swollen during the pandemic. A record 4.7 million had private health insurance through their employer in 2023, according to data compiled by the Association of British Insurers last year. The NHS also uses private hospitals to carry out procedures. The state-backed healthcare provider spent £2.1 billion in private hospitals last year, according to a report by LaingBuisson. It spent a further £1.5 billion at private clinics. The UK government announced earlier this year that the NHS would use private healthcare to carry out additional appointments, scans and operations in order to reduce waiting times. — Bloomberg This article first appeared in The Malaysian Reserve weekly print edition
The Star
a day ago
- The Star
Shining light to kill cancer cells
Cancer remains one of the leading causes of death worldwide, however, advancements in science continue to bring hope through better treatment options. One such option is photodynamic therapy (PDT), a promising and less invasive treatment that uses light, a special drug and oxygen molecules to target and destroy cancer cells. PDT is a type of cancer treatment that combines a special drug called a 'photosensitiser' with light to destroy cancer cells. The drug becomes active when exposed to a specific type of light, usually from a laser or LED (light-emitting diodes), and reacts with oxygen in the body. This reaction produces substances that kill cancer cells, disrupt nearby blood vessels and trigger a local immune response. Unlike treatments such as chemotherapy or radiation, PDT is very precise, targeting only the cancer cells while sparing most healthy tissue. It's especially useful for cancers close to the skin's surface or inside body cavities where light can reach. PDT is also less painful than surgery, leaves minimal scarring and has fewer side effects. Some photosensitisers have already been approved for treating certain pre-cancerous conditions and cancers in the United States and Europe. PDT works best for cancer cells that can be reached by light such as skin cancer, which means it's not suitable to treat all types of cancer. Availability of PDT locally In Malaysia, the use of PDT is gradually increasing as awareness of its benefits grows. Since it is a minimally invasive healthcare technology, PDT is gaining attention as an alternative or complementary treatment to traditional therapies. Although PDT isn't intended to replace surgery, chemotherapy or radiation, it's a valuable option for certain patients. Experts believe that improvements in technology, such as better photosensitisers, will help expand the use of PDT. However, more research is needed to fully establish its advantages over traditional treatments and its cost-effectiveness within Malaysia's healthcare system. Healthcare providers and institutions are also working to make PDT more affordable and accessible, while educating patients about its benefits and limitations. Is PDT effective? PDT has been proven to work well for various cancers, including skin cancer, oesophageal cancer, lung cancer, bladder cancer, biliary tract cancer and head and neck cancers. It's particularly helpful for managing symptoms in advanced or recurring cases that can't be cured. For skin cancer, PDT offers an added benefit: it leaves the skin looking better after treatment compared to surgery or other options. In some cases, PDT has also been found to improve survival rates and quality of life. Side effects, such as light sensitivity, pain, redness, or itching, are usually mild and manageable. Among PDT's uniqueness: > Minimally-invasive: H elps avoid the need for major surgery, leading to faster recovery times and less discomfort. > Precise targeting: The treatment focuses on cancer cells without harming most healthy tissues. > F ewer side effects: Unlike chemotherapy, PDT doesn't cause nausea, hair loss, or other widespread side effects. > Repeatable treatment: PDT can be safely repeated in the same area, unlike radiation therapy. Challenges and future directions While PDT has many advantages, it also has some limitations. The treatment only works for cancers that can be reached by light, which means it's not suitable for all types of cancer. Additionally, the photosensitising drugs used in PDT can make the skin and eyes sensitive to light for some time after treatment, requiring precautions like avoiding sunlight. Looking ahead, researchers are working on developing more effective drugs and better ways to deliver light to tumours, which could make PDT even more effective. Worldwide, efforts are being made to make PDT more affordable and available to patients. In short, PDT is an innovative treatment for certain types of cancer. It offers a less invasive and more targeted approach compared to traditional options. As awareness grows and technology improves, PDT has the potential to play a substantial role in cancer care. While challenges remain, the future of PDT is bright, bringing hope to cancer patients everywhere. Dr Lee Tze Yan is a senior lecturer and researcher in the field of biomedical science at the Institute of Medical Science Technology, Universiti Kuala Lumpur, Dr Nur Aininie Yusoh is a postdoctoral fellow in the Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, and Dr Loo Yan Shan holds a PhD in nanomedicine from Universiti Putra Malaysia, and is currently a research assistant in Monash University Malaysia. The information provided is for educational and communication purposes only, and should not be considered as medical advice. The Star does not give any warranty on accuracy, completeness, functionality, usefulness or other assurances as to the content appearing in this article. The Star disclaims all responsibility for any losses, damage to property or personal injury suffered directly or indirectly from reliance on such information.
Sinar Daily
2 days ago
- Sinar Daily
Earliest proof of humans using whale bone tools discovered
The bones, found on the northern Spanish coast in the Bay of Biscay, show that we have been underestimating our prehistoric ancestors, the European-led team of scientists said. 07 Jun 2025 04:01pm There was a boom in whale bones between 17,500 and 16,000 BC, when tools have been found as far away as Germany. - Photo illustrated by Sinar Daily PARIS - Scientists announced they have discovered the earliest evidence of humans using whale bones, finding weapons made from the remains of the massive mammals dating back more than 20,000 years. The bones, found on the northern Spanish coast in the Bay of Biscay, show that we have been underestimating our prehistoric ancestors, the European-led team of scientists said. Some of the bones were collected more than a century ago but were misidentified. The researchers used carbon-dating, as well as spectrometry analysis to determine what species the bones were from. - Photo illustrated by Sinar Daily Southwest Europe was much colder during the Upper Palaeolithic period, and the Atlantic Ocean was 120 metres (400 feet) lower than its current level. As the seas rose over the millennia, it destroyed or buried much of the proof that these hunter-gatherers interacted with the marine world, French prehistoric archaeologist Jean-Marc Petillon told AFP. This led to a "biased" vision that they only hunted inland beasts such as reindeer, bison and horses, the lead author of a new study in Nature Communications said. "Fortunately for us, people at the time transported a number of marine products inland," he added. Perched on a cliff, these humans would likely have been able to see blue, sperm, bowhead and other whales relatively near the shore, looking for food. Among their discoveries, the researchers found more than 60 fragments of whale ribs or vertebrae. These huge bones were carried up to five kilometres (three miles) to the top of a steep cliff, possibly to extract their oil. "These bones are very rich in fat," Petillon explained. Most of the bone tools were parts of weapons, such as the tips of spears. But it is "extremely unlikely" these ancient humans were able to hunt whales, the study said, adding that it was more likely that the huge animals had simply washed up on the beach. Some of the bones were collected more than a century ago but were misidentified. The researchers used carbon-dating, as well as spectrometry analysis to determine what species the bones were from. There was a boom in whale bones between 17,500 and 16,000 BC, when tools have been found as far away as Germany. "Then it stopped quite abruptly" for reasons that are not clear, Petillon said. The people of the time did not run out of bones, nor did they lose the bone-working techniques. "It could be a choice... like a fashion that lasts a millennium or two and then, at some point, stops," Petillon said. - AFP More Like This
